• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Does Assisted Reproduction Increase Risk of Breast, Ovarian, Uterine Cancer?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Williams et al. (BMJ, 2018) examined the risk of ovarian, breast, and uterine cancer in women who underwent assisted reproduction

METHODS:

  • Large, population-based, data linkage cohort study of women who underwent ART
    • Cohort records 1991 to September 2009, with those included from October 2009 to December 2010 providing consent
  • ART defined as “treatments or procedures that include in vitro handling of both human oocytes and sperm or embryos, for the purpose of reproduction.”
  • Fertility records for cohort members were linked to national cancer registrations
  • The main outcome measures observed first diagnosis of ovarian, breast, and uterine cancer
  • Potential confounders, such as parity and infertility diagnosis were included in the analysis

RESULTS:

  • 255,786 women contributed 2,257,789 person years’ follow up
  • There was no significant increased risk of
    • Uterine cancer: 164 observed v 146.9 expected; Standardized incidence ratio SIR 1.12 (95% CI, 0.95 to 1.30)
    • Breast cancer (overall): 2,578 observed vs 2,641.2 expected; SIR 0.98 (95% CI, 0.94 to 1.01)
    • Invasive breast cancer: 2272 observed vs 2,371.4 expected; SIR 0.96 (95% CI, 0.92 to 1.00)
  • There was significant increase in risk for
    • In situ breast cancer: 291 observed vs 253.5 expected; SIR 1.15 (95% CI, 1.02 to 1.29)
      • absolute excess risk (AER) 1.7 cases per 100,000 person years, (95% CI, 0.2 to 3.2)
      • associated with an increasing number of treatment cycles (P=0.03)
    • Ovarian cancer overall: 405 observed vs 291.82 expected; SIR 1.39 (95% CI, 1.26 to 1.53)
      • AER 5.0 cases per 100,000 person years (95% CI, 3.3 to 6.9)
    • Invasive ovarian cancer: 264 observed vs 188.1 expected; SIR 1.40 (95% CI, 1.24 to 1.58)
      • AER 3.4 cases per 100 000 person years, (95% CI, 2.0 to 4.9)
    • Borderline ovarian cancer: (141 observed vs 103.7 expected; SIR 1.36 (95% CI, 1.15 to 1.60)
      • AER 1.7 cases per 100,000 person years (95% CI, 0.7 to 2.8)
    • Note: Ovarian cancer risk
      • Increased risks of ovarian cancers limited to women with endometriosis and/or low parity
      • No observed increase in ovarian tumor risk for women treated because of only male factor or unexplained infertility

CONCLUSION:

  • The use of assisted reproduction did not increase risk for invasive breast or uterine cancer
  • In situ breast cancer was increased but not overall cancer
    • Authors suggest that potential explanations may include surveillance bias, chance, and potential confounding by factors such as higher socioeconomic status
  • Ovarian cancer risk was increased
    • Borderline cancer may related to surveillance bias as women in ART programs undergo multiple ultrasound examinations
    • The authors state that “our results suggest that this finding is more likely due to underlying patient characteristics, rather than assisted reproduction itself.”

Learn More – Primary Sources:

Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991-2010: data linkage study including 2.2 million person years of observation

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Does ART Increase Risk of Postpartum Hemorrhage?
Are Metformin or Statins Associated with Increased Risk for Ovarian Cancer in Women with Type 2 Diabetes?
USPSTF Releases Final Recommendation On Ovarian Cancer Screening

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site